Abstract
The poor prognosis for hepatocellular carcinoma (HCC) is associated with its high rate of recurrence in the cirrhotic liver. Therefore, development of effective strategies for preventing recurrence and secondary tumors will improve the clinical outcome of HCC patients. A malfunction of the retinoid X receptor-α (RXRα) due to phosphorylation by the Ras-MAPK signaling pathway is profoundly associated with liver carcinogenesis, and thus, may be a promising target for HCC chemoprevention. Acyclic retinoid (ACR), which inhibits Ras-MAPK activation and RXRα phosphorylation, successfully prevents HCC recurrence, thus improving patient survival. The fundamental concept of HCC chemoprevention by ACR is “clonal deletion,” which is defined as the removal of latent malignant clones from the liver before they expand into clinically detectable HCC. “Combination chemoprevention” using ACR as a key drug holds great promise of a new effective strategy for the prevention of HCC because of its synergism. ACR is also expected to prevent the development of HCC in obese people, who are at an increased risk to HCC, because this agent significantly inhibits obesity-related liver tumorigenesis in the rodent model. Here, we review the detailed effects of ACR on preventing HCC development, especially based on the results of our basic and clinical research.
Keywords: Acyclic retinoid, chemoprevention, clonal deletion, combination therapy, HCC, obesity, phosphorylated RXRα, lectin-reactive α-fetoprotein factor 3, branched chain amino acids, diethylnitrosamine, extracellular signal-regulated kinase, hepatitis B virus, hepatocellular carcinoma, hepatitis C virus, histone deacetylase, human epidermal growth factor receptor-2, interferon
Current Cancer Drug Targets
Title:Role of Acyclic Retinoid in the Chemoprevention of Hepatocellular Carcinoma: Basic Aspects, Clinical Applications, and Future Prospects
Volume: 12 Issue: 9
Author(s): Masahito Shimizu, Kenji Imai, Koji Takai and Hisataka Moriwaki
Affiliation:
Keywords: Acyclic retinoid, chemoprevention, clonal deletion, combination therapy, HCC, obesity, phosphorylated RXRα, lectin-reactive α-fetoprotein factor 3, branched chain amino acids, diethylnitrosamine, extracellular signal-regulated kinase, hepatitis B virus, hepatocellular carcinoma, hepatitis C virus, histone deacetylase, human epidermal growth factor receptor-2, interferon
Abstract: The poor prognosis for hepatocellular carcinoma (HCC) is associated with its high rate of recurrence in the cirrhotic liver. Therefore, development of effective strategies for preventing recurrence and secondary tumors will improve the clinical outcome of HCC patients. A malfunction of the retinoid X receptor-α (RXRα) due to phosphorylation by the Ras-MAPK signaling pathway is profoundly associated with liver carcinogenesis, and thus, may be a promising target for HCC chemoprevention. Acyclic retinoid (ACR), which inhibits Ras-MAPK activation and RXRα phosphorylation, successfully prevents HCC recurrence, thus improving patient survival. The fundamental concept of HCC chemoprevention by ACR is “clonal deletion,” which is defined as the removal of latent malignant clones from the liver before they expand into clinically detectable HCC. “Combination chemoprevention” using ACR as a key drug holds great promise of a new effective strategy for the prevention of HCC because of its synergism. ACR is also expected to prevent the development of HCC in obese people, who are at an increased risk to HCC, because this agent significantly inhibits obesity-related liver tumorigenesis in the rodent model. Here, we review the detailed effects of ACR on preventing HCC development, especially based on the results of our basic and clinical research.
Export Options
About this article
Cite this article as:
Shimizu Masahito, Imai Kenji, Takai Koji and Moriwaki Hisataka, Role of Acyclic Retinoid in the Chemoprevention of Hepatocellular Carcinoma: Basic Aspects, Clinical Applications, and Future Prospects, Current Cancer Drug Targets 2012; 12 (9) . https://dx.doi.org/10.2174/15680096112091119
DOI https://dx.doi.org/10.2174/15680096112091119 |
Print ISSN 1568-0096 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-5576 |
Related Books

- Author Guidelines
- Bentham Author Support Services (BASS)
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Influence of Leptin on Immunity
Current Immunology Reviews (Discontinued) Crocins: The Active Constituents of Crocus Sativus L. Stigmas, Exert Significant Cytotoxicity on Tumor Cells In Vitro
Current Cancer Therapy Reviews Novel Mediators of Vitamin D Signaling in Cancer and Obesity
Immunology, Endocrine & Metabolic Agents in Medicinal Chemistry (Discontinued) Meet Our Editorial Board Member
Anti-Cancer Agents in Medicinal Chemistry MiRNA-29: A microRNA Family with Tumor-Suppressing and Immune-Modulating Properties
Current Molecular Medicine Bisphosphonates in Lung Cancer: Can They Provide Benefits Beyond Prevention of Skeletal Morbidity?
Anti-Cancer Agents in Medicinal Chemistry Rational Targeting of the Urokinase Receptor (uPAR): Development of Antagonists and Non-Invasive Imaging Probes
Current Drug Targets Therapeutic Applications of Crocus sativus L. (Saffron): A Review
The Natural Products Journal Azole Antimycotics - A Highway to New Drugs or a Dead End?
Current Medicinal Chemistry Recent Developments on 1,2,4-Triazole Nucleus in Anticancer Compounds: A Review
Anti-Cancer Agents in Medicinal Chemistry New Approaches to the Modulation of the Cyclooxygenase-2 and 5-Lipoxygenase Pathways
Current Topics in Medicinal Chemistry The Proteolytic Activation of Angiogenic and Lymphangiogenic Growth Factors in Cancer – Its Potential Relevance for Therapeutics and Diagnostics
Current Medicinal Chemistry A Novel Small Molecule Inhibitor of FAK and IGF-1R Protein Interactions Decreases Growth of Human Esophageal Carcinoma
Anti-Cancer Agents in Medicinal Chemistry Optimising the Azeotropic Drying of 18F-Fluorine Wayto Improve the 18F-Fluorocholine Radiochemical Yield
Current Radiopharmaceuticals Hypoxia-Inducible Factor: A Potential Therapeutic Target for Rheumatoid Arthritis
Current Drug Targets Prevention of VP-16 Resistance by a Disiloxane, SILA409: Effects of SILA409 on the Expression of GRP78 in NCI-H446 Human Small Cell Lung Cancer Cells
Letters in Drug Design & Discovery Drug Transport Across the Blood-Brain Barrier and the Impact of Breast Cancer Resistance Protein (ABCG2)
Current Topics in Medicinal Chemistry Current Perspectives on Novel Drug Delivery Systems and Approaches for Management of Cervical Cancer: A Comprehensive Review
Current Drug Targets LncRNAs: Potential Novel Prognostic and Diagnostic Biomarkers in Colorectal Cancer
Current Medicinal Chemistry Antimicrobial Activity of Willowherb (Epilobium angustifolium L.) Leaves and Flowers
Current Drug Targets